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Abstract
Background: HIV-1 infected macrophages play an important role in rendering resting T cells permissive for infection, in
spreading HIV-1 to T cells, and in the pathogenesis of AIDS dementia. During highly active anti-retroviral treatment (HAART),
macrophages keep producing virus because tissue penetration of antiretrovirals is suboptimal and the efficacy of some is
reduced. Thus, to cure HIV-1 infection with antiretrovirals we will also need to efficiently inhibit viral replication in
macrophages. The majority of the current drugs block the action of viral enzymes, whereas there is an abundance of yet
unidentified host factors that could be targeted. We here present results from a genome-wide association study identifying
novel genetic polymorphisms that affect in vitro HIV-1 replication in macrophages.
Methodology/Principal Findings: Monocyte-derived macrophages from 393 blood donors were infected with HIV-1 and
viral replication was determined using Gag p24 antigen levels. Genomic DNA from individuals with macrophages that had
relatively low (n = 96) or high (n = 96) p24 production was used for SNP genotyping with the Illumina 610 Quad beadchip. A
total of 494,656 SNPs that passed quality control were tested for association with HIV-1 replication in macrophages, using
linear regression. We found a strong association between in vitro HIV-1 replication in monocyte-derived macrophages and
SNP rs12483205 in DYRK1A (p= 2.1661025). While the association was not genome-wide significant (p,161027), we could
replicate this association using monocyte-derived macrophages from an independent group of 31 individuals (p= 0.0034).
Combined analysis of the initial and replication cohort increased the strength of the association (p= 4.8461026). In addition,
we found this SNP to be associated with HIV-1 disease progression in vivo in two independent cohort studies (p= 0.035 and
p= 0.0048).
Conclusions/Significance: These findings suggest that the kinase DYRK1A is involved in the replication of HIV-1, in vitro in
macrophages as well as in vivo.
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Introduction
The development of highly active antiretroviral therapy
(HAART) has been the biggest achievement in HIV/AIDS
medicine. The current drug regimens can suppress plasma viral
load to (near) undetectable levels. However, often residual levels of
ongoing viremia can be detected [1,2], even after treatment
intensification [3], and complete eradication of HIV-1 from an
infected patient has not been achieved with HAART [4]. HAART
does not affect cells that are latently infected because in these cells
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the virus is not actively replicating. Activation of this viral reservoir
of latently infected resting CD4+ T cells [5] and residual
replication in monocytes/macrophages (reviewed in [6]) is
believed to be responsible for the increase in plasma viral RNA
levels that is observed after discontinuing HAART. Furthermore,
cells residing in the gut associated lymphoid tissue (GALT) [7,8],
the testis [9,10] and the central nervous system (CNS) [11,12] may
keep producing virus despite the use of antiretrovirals, because
drug penetration of these tissues is suboptimal. As a result of this
viral rebound and the existence of these sanctuary sites, HIV-1
infected individuals need to be on anti-HIV-1 medication for life.
The emerging drug resistance [13,14] and the severe side effects
(reviewed by [15]), high costs and suboptimal tissue penetration of
HAART necessitate transition from treatment to cure as soon as
possible.
The viral reservoir is established early after primary HIV-1
infection [16,17]. Although the precise mechanism is unknown, it
has been shown that infected macrophages play a critical role in
rendering resting CD4+ (but CCR52) T cells permissive for HIV-1
infection [18]. Targeting these HIV-1 infected macrophages will
not only help to eradicate the viral reservoir, but will also limit the
spread of HIV-1 to CD4+ T cells [19,20], prevent recruitment and
activation of these cells [21], and reduce macrophage mediated
apoptosis of T cells [22–25]. In addition, inhibiting or reducing
HIV-1 replication in macrophages/microglia will be of impor-
tance in preventing the onset of AIDS dementia and other
neurocognitive disorders associated with HIV-1 infection in the
brain, because macrophages/microglia play a crucial role in the
pathogenesis of these [26–28].
In the battle to cure HIV-1 infected individuals, identification of
novel targets for the development of drugs that can be used to
inhibit HIV-1 replication in macrophages will be required,
especially since macrophages are relatively resistant to the
cytopathic effect of HIV-1 replication [29]. Furthermore, tissue
macrophages residing in the sanctuary sites described above are
exposed to suboptimal levels of antiretrovirals, and the efficacy of
protease inhibitors (PIs) and other late stage inhibitors in
macrophages is substantially reduced [30,31]. This lower efficacy
of PIs in macrophages forms an obstacle in ending the ongoing
residual replication, since only intervention of the virus’ replication
cycle at stages post reverse transcription and integration will
prevent the production of new virions. Once the provirus is
integrated in the host genome, integrase and reverse transcriptase
inhibitors will no longer be effective in the cell.
Since the HIV-1 genome encodes only 15 proteins [32], it is
dependent on numerous host proteins for its replication [33].
Intervention of the interaction between HIV-1 and these HIV-1
dependency factors (HDFs) can potentially be used to inhibit
replication of the virus. Currently, the majority of drugs target
viral enzymes: HIV-1 protease, reverse transcriptase and integrase
(reviewed in [34]). The abundance of the HDFs offers great
promise for finding drugs that may be less prone to emerging drug
resistance of the virus, may better penetrate tissues and reach
sanctuary sites, and may effectively prevent the formation of new
virions in both monocytes/macrophages and CD4+ T cells.
However, it will be crucial to find a balance between limiting
the availability of HDFs and inhibiting viral replication, since most
host proteins essential for HIV-1 replication may also play critical
roles in the host cell.
Recently, a large number of host proteins that might be good
targets for novel drugs to inhibit HIV-1 replication was identified
[35–38]. These candidate proteins were found by measuring a
significant change in HIV-1 replication after a genome-
scale knock-down of host proteins, in different cell-lines. Since
macrophages are important as reservoir and in sanctuary sites, it is
also important to identify HDFs or host antiviral factors in these
cells. Because primary macrophages are notoriously difficult to
transfect and since HIV-1 replication in monocyte-derived
macrophages (MDM) can vary enormously between donors [39–
43] we decided to use a different approach and to actually exploit
this genetic variation between individuals. When monocyte
isolation, cell culture methods, medium and virus are all strictly
controlled, remaining variation in HIV-1 replication observed in
MDM from different donors can be assumed to be primarily of
genetic origin. Finding an association between host genetic traits
like a single nucleotide polymorphism (SNP) and HIV-1
replication in MDM would suggest that the locus tagged by this
SNP is of importance for replication of HIV-1 in these cells. We
therefore searched genome-wide for associations between SNPs
and in vitro HIV-1 replication specifically in monocyte-derived
macrophages.
Results
Association between single nucleotide polymorphism in
the kinase DYRK1A and HIV-1 replication in monocyte-
derived macrophages
A total of 494,656 SNPs passing quality control were tested for
association with levels of HIV-1 replication in monocyte-derived
macrophages (MDM) using linear regression. With data from 191
healthy blood donors whose MDM ranked in the bottom quartile
with lowest (n= 95 donors) or top quartile with highest (n= 96
donors) Gag p24 production 14 days post infection with HIV-1 [39]
(Table 1), we found strongest associations for SNPs in the genes
PDE8A (rs2304418, p=2.461026 and rs12909130, p=8.361026),
UBR7 (rs2905, p=7.061026), MOAP1 (rs1046099, p=9.961026
and rs1270629, p=1.0961025), DYRK1A (rs12483205, p=
2.261025) and SPOCK3 (rs17519417, p=2.561025) (Figure 1,
Table S1). The two SNPs in PDE8A were found to be in high
linkage disequilibrium (LD; r2 = 0.97), whereas only a moderate
degree of LD was found between rs1046099 and rs1270629 in
MOAP1 (r2 = 0.54) (Table 2). Table 2 shows all other SNPs
associated with HIV-1 replication in MDM (cutoff p val-
ue= 561025; n= 16), and includes information about LD, location,
number of donors homozygous for the minor allele (MIN) and
empirical p values after permutation testing. Genotyping results for
none of these 16 SNPs violated Hardy-Weinberg equilibrium.
The empirical p values for linear regression using 107
permutations of the genotype for each SNP in Table 2 were in
close agreement with the asymptotic p values (Table 2). However,
none of these SNPs remained statistically significant after a
conservative correction for multiple testing (Bonferroni threshold
of p,161027; Figure S1). We next investigated the association
between the SNPs in the five most promising genes (rs2304418 in
PDE8A, rs2905 in UBR7, rs1046099 and rs1270629 in MOAP1,
rs12483205 in DYRK1A and rs17519417 in SPOCK3) in a second
group of blood donors (replication cohort). MDM from an
independent group of 32 healthy blood donors were infected with
HIV-1 and Gag p24 levels were measured 14 days after infection.
One donor was found to be homozygous for the 32 base pair
deletion in CCR5, rendering the cells completely resistant to
infection with CCR5-using HIV-1, and results obtained with
macrophages from this donor were excluded from further analysis.
The associations for the SNPs in PDE8A, UBR7, MOAP1 and
SPOCK3 with Gag p24 production by MDM could not be
replicated in this small group of 31 donors (data not shown).
However, in this replication cohort we again found a strong
association between SNP rs12483205 in DYRK1A and in vitro HIV-
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Figure 1. Association between HIV-1 replication in monocyte-derived macrophages (MDM) and the genotypes for the SNPs
rs12483205 in DYRK1A, rs2304418 in PDE8A, rs2905 in UBR7, rs1046099 and rs1270629 in MOAP1, and rs17519417 in SPOCK3. Only
donors with MDM with low (n= 95) or high (n = 96) HIV-1 replication in vitro were included in the genome-wide SNP analysis. This selection of donors
with a more extreme phenotype explains the absence of circles in the middle section of the graphs. MAJ, homozygous for the major allele; HZ,
heterozygote; MIN, homozygous for the minor allele.
doi:10.1371/journal.pone.0017190.g001
Table 1. Characteristics of healthy donors whose macrophages showed either low, intermediate, or high HIV-1 replication in vitro.
In vitro HIV-1 replication in monocyte-derived macrophages
Low Intermediate High p valuea
Donors (number) 95 202 96 n/a
Gender (males:females) 52:43 unknownb 53:43 0.948c
Age (years, mean 6 SD) 46611 49611 47612 0.371d
European ancestry (number, %) 95e, 100% 202f 96e, 100% n/a
Normalized p24, log10 (mean 6 SD) 20.6560.34 20.0160.16 0.4960.18 ,0.0001d
n/a, not applicable.
SD, standard deviation.
ap values only for comparison between donors with MDM that produced low levels of Gag p24 and donors with MDM that had high p24 production after infection with
HIV-1.
bInformation was not available.
cPearson chi-square test.
dTwo-sample t-test.
eSelf-reported, Structure and Eigenstrat analysis (for details see Materials and Methods section).
fSelf-reported only (for details see Materials and Methods section).
doi:10.1371/journal.pone.0017190.t001
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1 replication in macrophages (p=0.0034) (Figure 2, Table S2),
also after correction for cell number and normalization
(p=0.0081; n= 28, information on cell number was missing for
3 donors) (data not shown, Table S2). This association remained
significant after correction for multiple testing (Bonferroni
corrected p=0.020 (0.003466 SNPs for which we tried to
replicate the association)) and when calculating the empirical p
value for linear regression using 105 permutations of the genotypes
(p=0.004) (Table S1).
The DYRK1A SNP rs12483205 genotypes were then also
determined for the 202 donors with MDM that had intermediate
Gag p24 levels in the supernatant [39]. Adding results from this
group of donors did not change the strength of the association
between the rs12483205 genotype and HIV-1 replication in
MDM (p=2.0961025; n = 393) (Figure S2A, Table S3). As
expected, combined analysis of both the initial group of donors
(n = 393) and the replication cohort (n = 28) revealed an increase
in the strength of the association for rs12483205 in DYRK1A
(p=4.8461026) (Figure S2B, Table S4).
Effect of rs12483205 in DYRK1A is independent of the
CCR5 D32 genotype
The 32 base pair deletion in CCR5 strongly affects replication of
HIV-1, also in macrophages in vitro [39]. MDM from donors that
were heterozygous for this 32 base pair deletion (n = 33) had
significantly lower HIV-1 replication than donors without the
deletion (n= 158) (p=0.0036, two-sample t-test) (Table S5).
There were significantly more CCR5 wt/D32 heterozygous donors
present in the rs12483205 heterozygous (HZ) and rs12483205
MIN groups (p=0.02, Fisher Exact test). After adjusting for the
CCR5 wt/D32 heterozygous genotype by using it as a covariate in
multivariate analysis, the strength of the association between the
Table 2. SNPs (p,561025) associated with in vitro HIV-1 replication in monocyte-derived macrophages.
SNP
Closest
gene Location Chr. Position p value Empirical p*2
# MIN
donors Linkage disequilibrium (r2)*3
1 rs2304418 PDE8A Intronic 15 85640983 2.4161026 2.3061026 15 0.97m
2 rs2905 UBR7 39 UTR 14 93693422 6.9661026 8.0061026 16 0.35c 0.28&
3 rs12909130 PDE8A Intronic 15 85590501 8.3161026 8.7061026 15 0.97m
4 rs1046099 MOAP1 39 UTR 14 93649501 9.9461026 1.1261025 17 0.28& 0.54N
5 rs1270629 MOAP1 Flanking 39 UTR 14 93646409 1.0961025 1.1561025 6 0.35c 0.54N
6 rs2828074 Intergenic 21 24710202 1.4161025 1.4561025 - *4
7 rs12483205*1 DYRK1A Intronic 21 38740824 2.1661025 2.2661025 8
8 rs17519417 SPOCK3 Intronic 4 167659185 2.5261025 2.4161025 - *4
9 rs16884060 Intergenic 5 10060297 3.2061025 3.1261025 4
10 rs7856177 SPTLC1 Intronic 9 94839342 3.4261025 3.6461025 1 0.26.
11 rs8070997 ACCN1 Intronic 17 31428130 3.6661025 3.3861025 2
12 rs1792745 LOC642484 Intronic 18 53804993 3.8661025 4.4561025 8
13 rs7042102 SPTLC1 Flanking 39 UTR 9 94763790 4.0161025 4.2561025 28 1.00b 0.26.
14 rs10739923 SPTLC1 Flanking 39 UTR 9 94746291 4.0161025 4.2361025 28 1.00b
15 rs12361072 Intergenic 11 23086211 4.9361025 5.4661025 34 1.00X
16 rs2468574 Intergenic 11 23096397 4.9361025 5.4661025 34 1.00X
Chr., chromosome.
*1The effect of the SNP in DYRK1A was replicated with monocyte-derived macrophages from an independent group of 31 donors.
*2Empirical p value calculated for linear regression using 107 permutations of the genotypes.
*3Measure for the magnitude of linkage disequilibrium (r2) between SNPs with identical symbols (m, b, c, ., &, N or X).
*4Major genotype is the heterozygous genotype (,50%); both classes of homozygous genotypes equally present (,25% each).
doi:10.1371/journal.pone.0017190.t002
Figure 2. Significant association between rs12483205 and in
vitro replication of HIV-1 in macrophages derived from an
independent group of 31 healthy blood donors. The negative
association between the rs12483205 minor allele and Gag p24 levels in
MDM culture supernatant 14 days after inoculation with HIV-1, was
found to match with the results from the genome-wide association
study. Open circles represent results from donors with the CCR5 D32
wild-type genotype, filled circles from donors with the CCR5 wt/D32
heterozygous genotype. MAJ, homozygous for the major allele; HZ,
heterozygote; MIN, homozygous for the minor allele.
doi:10.1371/journal.pone.0017190.g002
N
N
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DYRK1A rs12483205 genotype and HIV-1 replication in MDM
decreased (from p=2.261025 to p=1.261024), but persisted
(Table S5). Moreover, the association of rs12483205 in DYRK1A
with HIV-1 replication in MDM in the replication cohort of 31
donors, was independent of the CCR5 D32 genotype (p=0.0022,
and p=0.007 when corrected for cell number and normalized for
date of isolation; Table S2), suggesting only a spurious
relationship between the CCR5 locus on chromosome 3 and
SNP rs12483205 in DYRK1A located on chromosome 21. Indeed,
this was supported by results from the multivariate analysis on the
total group of 393 donors (p=3.861025, Table S3) and on the
combined group of 421 (393+28 donors from the replication
cohort) individuals (p=9.761026, Table S4).
Minor variant of SNP rs12483205 in DYRK1A is associated
with slower disease progression
Next, we investigated the association between HIV-1 load or
disease course in vivo and the six most promising SNPs identified in
our GWAS (rs12483205 in DYRK1A, rs2304418 in PDE8A, rs2905
in UBR7, rs1046099 and rs1270629 in MOAP1 and rs17519417 in
SPOCK3). Results from the Amsterdam Cohort Study (ACS)
GWAS on HIV/AIDS disease progression (Van Manen et al.,
manuscript in preparation) and three previously published HIV-1
cohort studies with GWAS data were used: the CHAVI cohort
[44], the GRIV [45,46] and the MACS [47]. To avoid possible
overlap between the replication cohorts, MACS samples were
removed from the CHAVI cohort and the analysis was performed
only using data from the European subset (EURO-CHAVI).
Illumina Human Hap BeadChips were used for genotyping
DNA samples in the EURO-CHAVI cohort (550 K/1 M), the
GRIV (300 K) and the ACS (300 K), whereas in the MACS they
used Affymetrix Human 500 K GeneChips for the first stage
discovery analysis [47]. Using different genotyping platforms
results in genotype data for a different set of SNPs, which
occasionally makes it necessary to estimate the unobserved
genotypes, a process called SNP imputation [48]. When the
imputation score (a measure for the reliability of the imputation)
was below 0.8, imputation was considered unreliable and data was
therefore not used. Results for SNPs rs2905 (UBR7), rs1046099
(MOAP1), rs1270629 (MOAP1) and rs12483205 (DYRK1A) in the
MACS, and rs1046099 (MOAP1) and rs17519417 (SPOCK3) in
both the GRIV and the ACS, were based on SNP imputation. The
imputation score for rs12483205 in DYRK1A was 0.94, and ,0.8
for rs2905, rs1046099 and rs1270629. For rs1046099 and
rs17519417 the imputation scores were 0.88 and 1 respectively,
in the GRIV and in the ACS.
Table 3 shows the results for association testing between
disease progression or viral load and the identified SNPs in
DYRK1, PDE8A, UBR7, MOAP1 and SPOCK3. No significant
associations or trends were found for the SNPs in PDE8A, UBR7 or
MOAP1. However, SNPs rs12483205 in DYRK1A and rs17519417
in SPOCK3 were significantly associated with in vivo endpoints in
at least one of the four independent cohorts analyzed. While no
association was observed in the GRIV and the ACS, we found an
association between rs12483205 in DYRK1A and disease progres-
sion in the MACS (p=0.0048, Table 3) and in the EURO-
CHAVI cohort (p=0.035, Table 3). In both cohort studies the
minor allele of rs12483205 was associated with slower disease
progression, which was consistent with the decreased in vitro
replication of HIV-1 in MDM for the minor allele of rs12483205.
Furthermore, there was an association between SNP genotype
and progression to AIDS for rs17519417 in SPOCK3 in the MACS
[47] (p=0.012, Table 3), with the C allele associated with slower
progression. This was also in agreement with the association with
lower in vitro HIV-1 replication in MDM in our study.
SNP rs12483205 is localized near the 59 untranslated
region of DYRK1A transcript variant 3
The DYRK1A mRNA has multiple splice forms. According to
the NCBI Entrez Gene database [49] the alternative splicing can
yield four different DYRK1A transcript variants, referred to as
transcripts 1, 2, 3 and 5 (Figure 3). In addition to differences in
the number or size of exons, there is also variation in the length of
both the 59 and 39 untranslated region (UTR). Transcript variant
1 encodes the longest isoform (763 amino acids), which is a
fraction larger than isoform 2 (754 amino acids). Isoforms 3 and 5
lack a C-terminal part of the full length protein (179 and 234
amino acids respectively), and consequently miss among others a
poly-His domain. SNP rs12483205 in DYRK1A lies ,900 base
pairs downstream of the most distant 59 UTR fragment of
Table 3. Results (p values) for association testing using the additive analysis model, between disease progression or viral load and
the SNPs in DYRK1A, PDE8A, UBR7, MOAP1 and SPOCK3.
EURO-CHAVI GRIV MACS ACS
SNP (gene)
viral load
at set point
progression
(CD4 T cells)
non-
progressors -
controls
rapid
progressors -
controls
rapid –
moderate -
non-progressors
AIDS
(def. ’87)
AIDS
(def. ’93)
AIDS
related
death
rs12483205 (DYRK1A) .0.1 0.035* .0.1 .0.1 0.0048*# 0.059*# 0.059 .0.1
rs2304418 (PDE8A) .0.1 .0.1 .0.1 .0.1 .0.1 .0.1 .0.1 .0.1
rs2905 (UBR7) .0.1 .0.1 .0.1 .0.1 N.A. N.A. .0.1 .0.1
rs1046099 (MOAP1) .0.1 .0.1 .0.1 .0.1 N.A. N.A. 0.075# .0.1
rs1270629 (MOAP1) .0.1 .0.1 .0.1 .0.1 N.A. N.A. .0.1 .0.1
rs17519417 (SPOCK3) .0.1 .0.1 .0.1 .0.1 0.012*# 0.086*# .0.1 .0.1
All p values ,0.1 are shown.
*Effect of the minor allele consistent with our findings.
#Based on SNP imputation; imputation score .0.8.
N.A., not available (imputation score ,0.8); EURO-CHAVI, European subset of the CHAVI cohort (n = 1,280 for viral load and n = 634 for disease progression) [44]; GRIV,
Genomics of Resistance to Immunodeficiency Virus cohort (275 non-progressors vs. 1,352 controls [45], and 85 rapid progressors vs. 1,352 controls [46]); MACS,
MultiCenter AIDS Cohort Study cohort (n = 156) [47]; ACS, Amsterdam Cohort Study (n = 404; Van Manen et al., manuscript in preparation).
doi:10.1371/journal.pone.0017190.t003
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transcript variant 3 (Figure 3). PCR analysis with primers able to
discriminate between all four known transcript variants (Figure
S3) confirmed the presence of transcript variants 1, 2 and 3 in
MDM, and in the glioma cell line U87 that was used as a positive
control for the PCR (Figure 4). Transcript variant 5 was present
in U87 cells, but was not detected in MDM (Figure 4). The
DYRK1A gene region is devoid of known SNPs that are in high
LD with rs12483205; currently available data on LD in this region
does not reveal any SNP with an r2.0.5 in the Caucasian
population [50–52].
Discussion
Genome-wide studies provide a hypothesis free and unbiased
approach to identify novel associations between genetic factors
and the studied phenotype. Selecting donors with a more extreme
in vitro phenotype allowed us to identify a number of promising
SNPs in genes not previously linked to HIV-1, that are associated
with replication levels of HIV-1 in monocyte-derived macrophages
(MDM). Importantly, the association between rs12483205 in
DYRK1A and in vitro HIV-1 replication could be replicated using
Figure 3. Schematic representation of the DYRK1A gene region, depicting all four transcript variants (1, 2, 3 and 5) and the
localization of SNP rs12483205. Untranslated regions (UTR) are shown as open blocks, whereas exons are shown as filled blocks. SNP rs12483205
lies in close proximity to a part of the 59 UTR unique for splice variant 3.
doi:10.1371/journal.pone.0017190.g003
Figure 4. Detection of different DYRK1A transcript variants in macrophages. Amplicons were generated by PCR on cDNA from U87 cells,
used as a positive control for the PCR, and from monocyte-derived macrophages (MDM) obtained from three individuals, using DYRK1A transcript
variant specific primers. DYRK1A transcript variants 1, 2 and 3 were detected in MDM and U87 cells (panel A, B and C respectively). Transcript variant 5,
however, was only convincingly detected in U87 cells, and not in MDM. Numbers on the left side of each picture indicate the size (in base pairs, bp)
for the corresponding DNA fragment of the DNA ladder or PCR amplicons. 1 kb, 1 kb DNA ladder; 100 bp, 100 bp DNA ladder.
doi:10.1371/journal.pone.0017190.g004
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MDM from an independent small group of donors, and was
independent of the CCR5 D32 genotype. Moreover, this SNP in
DYRK1A was significantly associated with in vivo endpoints in two
independent cohorts. SNPs in four other genes were not replicated
in the small in vitro replication cohort, possibly reflecting
insufficient power. However, the identified SNP in SPOCK3 was
replicated in one of the in vivo GWAS.
The use of, or even the dependence on, certain cellular factors
by HIV-1 can differ between the various target cells such as T cells
and macrophages. For example, the cellular factors GATA-3,
ETS-1 and NF-ATc are T cell specific [53,54], whereas C/EBPb
is required for HIV-1 replication in macrophages, but not in T
cells [55,56]. To test whether our top SNPs were macrophage-
specific, we investigated if these SNPs were also associated with
HIV-1 replication in CD4+ T cells. Genotyping DNA from 128
blood donors for whom the level of HIV-1 replication in PHA-
stimulated CD4+ T cells was previously determined [57], revealed
no association between the level of HIV-1 replication in T cells
and the genotype of the five SNPs tested. This finding could
indeed be an indication that the effects of some of the SNPs that
we have identified are macrophage-specific, but also could reflect
lack of power (n = 128, and not only extreme phenotypes). The
finding that the SNP rs12483205 in DYRK1A was associated with
in vivo endpoints could indicate a role for HIV-1 infection of
macrophages in disease progression.
DYRK1A is a kinase that phosphorylates serine and threonine
residues. The gene encoding for this kinase is located on the Down
syndrome critical region on chromosome 21 which is thought to be
responsible for the features of Down syndrome. For this reason,
the emphasis of DYRK1A research has been on its role in trisomy
21 and neurological dysfunction [58–63]. Substrates for DYRK1A
comprise among many others the transcription factors CREB [64],
FKHR [65], GLI1 [66], NFAT [67,68] and STAT3 [69]. This
large number of protein interactions and substrates described for
DYRK1A strongly suggests it plays an important role in the
regulation of gene expression and cell function. While the
molecular mechanisms underlying the effect of DYRK1A on
HIV-1 replication in MDM remain to be unraveled, the critical
role of kinases in general for the replication of HIV-1 in
macrophages has already been established [70–75].
Both SNPs in MOAP1 that we found to be associated with HIV-
1 replication in MDM are in close proximity to the UBR7 gene
region (44 and 47 kb for rs1046099 and rs1270629 respectively),
yet the degree of LD is fairly low (r2 = 0.28 and 0.35 for rs1046099
and rs1270629 respectively) which could indicate that the
observed associations for the SNPs in UBR7 and MOAP1 with
HIV-1 replication are independent of each other. MOAP1 is a
homodimeric protein that binds both proapoptotic (BAX) and
prosurvival (BCL2) molecules [76]. MOAP1 has no known direct
effect on HIV-1 replication. However, it is well recognized that
HIV-1 infection affects the regulation of programmed cell death
(reviewed in [77]) and that host factors induce apoptosis during the
infection process to prevent viral dissemination [78,79]. This host
factor-induced apoptosis was found to be associated with reduced
HIV-1 replication in MDM [78,79]. Only very little is known
about UBR7. However, studies on other members of the UBR
family support the hypothesis that UBR7 is be associated with
HIV-1 replication. Proteins of the UBR family are E3 ligases that
recognize degradation signals at the N-terminus of proteins (N-
degrons) and conjugate ubiquitin to the target protein [80]. The
HIV-1 protein integrase contains an N-terminal phenylalanine
that is recognized as a degradation signal by UBR1, UBR2 and
UBR4 [80,81] and indeed, these proteins control the level of HIV-
1 integrase [80]. Knocking down UBR1, UBR2 and UBR4
resulted in higher levels of HIV-1 integrase [80], yet inhibition of
the proteasome resulted in a further increase of HIV-1 integrase
[80], suggesting the presence of other E3 ligases that target N-
degrons of HIV-1 integrase. The results of our study could indicate
that UBR7 affects HIV-1 replication in MDM through regulation
of HIV-1 integrase.
In addition to the SNP in DYRK1A we also found associations
for rs17519417 in SPOCK3 with time to progression to AIDS.
SPOCK3, also referred to as Testican 3, is a proteoglycan and one
of the components of the extracellular matrix. It inhibits
processing of metalloproteinase 2 (MMP-2) [82]. There are
indications that MMP-2 might play a role in the pathogenesis of
AIDS-related Kaposi’s sarcoma [83,84] or HIV-1 associated
dementia [85–87].
While we could not replicate the GWAS result for the SNP in
PDE8A, results from other in vitro studies strongly suggest that
PDE8A plays an important role in the replication cycle of HIV-1.
Phosphodiesterase 8A (PDE8A) specifically hydrolyses cAMP to
AMP. Previous studies that showed strong inhibition of HIV-1
replication after efficient knock-down [38], interaction between
HIV-1 Tat protein and PDE8A [88,89] and the deleterious effect
of high levels of cAMP on HIV-1 replication [90], all profoundly
suggest that this type of phosphodiesterase is indeed important for
in vitro HIV-1 replication.
To further validate our findings it will be important to also
investigate the role of the identified SNPs and genes in HIV-1
related pathologies that are more specifically affected by
macrophages, such as HIV-1 associated dementia and AIDS
related lymphomas [91]. Here, the contribution of macrophages
could be more eminent than in cohorts that study time to
progression to AIDS, which might be more T cell dependent,
especially since sometimes AIDS is defined by CD4+ T cell counts.
Follow-up experiments that will identify the causal SNP and
study its effect on the primary protein structure, protein folding,
alternative splicing or expression (level, localization and timing)
will be essential to better understand the precise mechanism by
which this SNP affects HIV-1 replication in MDM. This will be a
valuable step that might help determine if, and to what extent the
host protein can be efficiently targeted by novel antiretroviral
drugs. Finding a SNP in a gene encoding the kinase DYRK1A
that affects HIV-1 replication, holds great promise for finding
molecules to be safely used as potentially novel anti-HIV-1
medication [92].
Materials and Methods
Ethics statement
This study has been conducted in accordance with the ethical
principles set out in the declaration of Helsinki, written informed
consent was obtained from all participants and was approved by
the Medical Ethics Committee of the Academic Medical Center in
Amsterdam and the Ethics Advisory Body of the Sanquin Blood
Supply Foundation, The Netherlands.
Study population
We previously determined the ability of HIV-1 to replicate in
monocyte-derived macrophages (MDM) from 429 different
healthy seronegative blood donors [39]. In brief, Gag p24 levels
were measured in MDM culture supernatant 14 days post
infection by an in-house enzyme-linked immunosorbent assay.
To correct for differences in the number of viable MDM present at
day 14 post infection, p24 levels were expressed per 10,000 cells.
Since monocyte isolations were performed in four time frames and
by two operators, p24 levels were normalized by dividing through
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the median per period and operator. These normalized p24 levels
were subsequently used as a measure for in vitro HIV-1 replication
in MDM.
After excluding donors that were homozygous for the 32 base
pair deletion in CCR5 (n = 5) or not from European decent
(n = 30), we selected 192 individuals whose MDM gave the highest
(n = 96) or the lowest (n = 96) p24 production in vitro, for SNP
genotyping; thus representing two groups of donors with MDM
that had a more extreme phenotype (Table 1). Inclusion of
donors with extreme phenotypes is known to increase power in
genetic association studies [93]. These two groups with a more
extreme phenotype were separated by a group with intermediate
HIV-1 replication in MDM which consisted of 202 donors. There
was no difference in age or distribution of males and females
between the group with MDM that had low HIV-1 replication
and the group with MDM that had high Gag p24 production
(p=0.95, Pearson chi-square test and p=0.37, two sample t-test,
respectively; Table 1). One donor from the group with low in vitro
HIV replication in MDM was excluded for further analysis
because the corresponding DNA samples did not pass the quality
control (SNP call rate ,0.98; see paragraph ‘‘Quality control of
SNP genotyping data’’ below).
Cells (monocytes and lymphocytes) used to replicate the
genome-wide association study (GWAS) findings were derived
from blood samples collected from an independent group of 32
healthy blood donors (replication cohort).
Genotyping
Peripheral blood lymphocytes (PBL) from each donor were used
for DNA isolation using the QIAamp ‘‘DNA blood mini kit’’
(Qiagen, Valencia, CA, USA). For the two groups of donors whose
MDM had highest (n = 96 donors) or lowest (n = 96 donors) in vitro
HIV Gag p24 production, we used the Illumina Infinium Human
Hap 610-Quad BeadChip (Illumina, San Diego, CA, USA) [94]
for SNP genotyping. ABI TaqManH SNP genotyping assays were
used to genotype DNA from the replication cohort for rs12483205
(C_31609775_10), rs12909130 (C_1342209_10) as a proxy for
rs2304418, rs2905 (C_3236245_20), rs1046099 (C_7585751_10)
and rs17519417 (C_33238869_10) (Applied Biosystems, Carlsbad,
CA, USA). All TaqManH assays were run on a LightCyclerH 480
system (Roche, Basel, Switzerland) using the following amplifica-
tion cycles: 10 min 95uC; 50 cycles of 15 sec 95uC, 1 min 60uC.
Quality control of SNP genotyping data
One donor DNA sample did not pass the minimal genotyping
call rate threshold of 98% and this sample was excluded for further
SNP association analysis. The Illumina 610Q SNP bead chip
contained 620,901 markers to detect common genetic variation,
including 21,890 markers for copy number variation (CNV). After
excluding a total of 126,245 SNPs (minor allele frequency ,0.05,
or SNP call frequency ,0.98, or SNPs for which there were no
donors homozygous for the minor allele) and copy number
variation markers, 494,656 SNPs were left to be tested for
association between genotype and in vitro HIV-1 replication
MDM. Violation of Hardy-Weinberg equilibrium was assessed
post-analysis for all SNPs with p,561025. Gender calls in
BeadStudio (version 3.1.3.0) were compared with self-reported
gender and were found to match for all donors (n = 191).
Identification of population stratification
Donors who reported that either one or more parents or grand
parents were born outside of Europe had been excluded from
further analysis (as described in the paragraph ‘‘Study population’’
above). The genetic homogeneity of the genotyped donors whose
MDM gave lowest (n = 96) or highest (n = 96) Gag p24 production
in vitro was confirmed by both Structure [95] and Eigenstrat [96]
analysis. As expected, the Q-Q plot displaying the normality of the
p value distribution did not show deviations from what is expected
under the null hypothesis (l=1.0024; l=1.0 is expected with a
null hypothesis; Figure S4), indicating little effect of population
stratification.
Statistical analysis
We set a lower detection limit (background signal) for the
normalized p24 values based on the highest results that we found
for a donor that was homozygous for the 32 base pair deletion in
CCR5. Normalized p24 values were log10 transformed to allow for
parametric testing.
Association was tested assuming an additive relationship
between the genetic variants (wild-type, heterozygous and
homozygous for the minor allele) and phenotype, using linear
regression. Permutation testing was done to empirically determine
the corresponding p value based on the observed linear regression
F-statistic relative to the distribution of the F-statistic estimated
from 107 permutations of the genotypes. All R code and data used
for the calculations can be found as supplementary online material
(Tables S1, S2, S3, S4 and S5 and text file ‘‘R Scripts S1’’).
Linkage disequilibrium (LD) between SNPs was calculated using
data obtained from genotyping DNA from our studied population
(n= 191) with the Illumina SNP chip, using Haploview software
(version 4.2) [50]. SNP genotype imputations for our study
population were performed using Impute software [48] and the
Caucasian HapMap population (release 21) as the reference panel.
DYRK1A transcript detection in monocyte-derived
macrophages
Seven day old MDM and U87 cells were used for RNA isolation
and subsequent cDNA synthesis using the Roche ‘‘high pure RNA
isolation’’ and ‘‘transcriptor first strand cDNA synthesis’’ kit
(Roche, Basel, Switzerland). To uniquely detect the presence of
transcript variants 1, 2, 3 and 5, we used primer pairs 59-
TGATATTGTCATGTTACAGAGGCGG-39 (forward) and 59-
CTGACGCACCTGGGGACTG-39 (reverse), 59-TGTCTCTG-
AGGTTCTTTTCCAGTG-39 (forward) and 59-AGCACCC-
TCTCAATTCCCAATGCC-39 (reverse), 59-GCTCGCACGTG-
GTTCATTTGCT-39 (forward) and 59-TCCTTAGACAGGA-
ACGTCATGAACCT-39 (reverse), and 59-CAGGAGGACCT-
GGTGGGCGA-39 (forward) and 59-TGCTGACGCACCT-
GAGCTTG-39 (reverse) respectively (Figure S3). For the
detection of transcript variants 1, 2, 3 and 5 the following
amplification cycles were used: 2 min 95uC; 35 cycles of 30 sec
95uC, 30 sec 62uC (64uC for transcript 1), 30 sec 72uC (90 sec for
transcript 1); 10 min 72uC.
Supporting Information
Figure S1 Manhattan plot displaying the -log p value of the
association for 494,656 SNPs tested with in vitro replication of
HIV-1 in monocyte-derived macrophages. Signals are seen for
SNPs in chromosome 14 (SNPs in UBR7 or MOAP1), 15 (SNPs in
PDE8A) and 21 (SNP rs12483205 in DYRK1A, and intergenic SNP
rs2828074 .14 Mb upstream of rs12483205). The threshold for
genome-wide significance is -log p.7 (dashed line). The plot was
created using the WGA viewer software version 1.26G [97].
(TIF)
Figure S2 Association between HIV-1 replication in monocyte-
derived macrophages (MDM) and the SNP rs12483205 genotype
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in the gene DYRK1A, for the total group of 393 blood donors (A),
and this group of donors joined with donors from the replication
cohort for which we had normalized data (n = 28; total n = 421)
(B). DNA from donors with MDM that had low (n= 95) or high
(n = 96) HIV-1 replication in vitro was used for the genome-wide
association screen. Inclusion of genotype and normalized p24 data
from donors with MDM that had intermediate Gag p24
production did not change the strength of the association
(p=2.0961025), whereas combining the initial group of donors
(n = 393) and the replication cohort (n = 28) increased the strength
of the association (p=4.8461026). MAJ, homozygous for the
major allele; HZ, heterozygote; MIN, homozygous for the minor
allele.
(TIF)
Figure S3 Schematic representation of the alignment of all four
known DYRK1A mRNAs. Primers are depicted as arrows and were
used to amplify a unique region for each of the transcripts. The
start and stop codons are shown as green and red vertical lines
respectively.
(TIF)
Figure S4 Q-Q plot showing the expected and observed
distribution of the p values. The line and the corresponding
Lambda (l) suggest there are no systematic differences in allele
frequencies between subpopulations in our study population due
to differences in genetic background of donors. The plot was
created using the WGA viewer software version 1.26G [97].
(TIF)
Table S1
(TXT)
Table S2
(TXT)
Table S3
(TXT)
Table S4
(TXT)
Table S5
(TXT)
R Scripts S1
(TXT)
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